Evidence map›Paper›PMID 36474029›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2023

A novel circ_0018553 protects against angiotensin-induced cardiac hypertrophy in cardiomyocytes by modulating the miR-4731/SIRT2 signaling pathway.

Huihua Zuo, Liang Li, Xiaoqing Wang, Shiyu Chen, Zhiyong Liao, Shanyin Wei, Huanjun Ruan, Teng Li, Junyu Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Huihua Zuo *Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, 518057, China.
Liang Li *Department of Cardiology, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, 518057, China.
Xiaoqing WangDepartment of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, 518057, China.
Shiyu ChenDepartment of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, 518057, China.
Zhiyong LiaoDepartment of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, 518057, China.
Shanyin WeiDepartment of Cardiology, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, 518057, China.
Huanjun RuanDepartment of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, 518057, China.
Teng LiDepartment of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, 518057, China. gdmc99@163.com.
Junyu ChenDepartment of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, 518057, China. jonymod@163.com.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNGuangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the complicated pathophysiology of cardiac hypertrophy, there are no effective therapies for the treatment of pathological cardiac hypertrophy. Accumulating evidence has demonstrated that circRNAs participate in the pathophysiology of cardiac hypertrophy. In this study, we investigated the regulatory mechanisms of the novel circ_0018553 in angiotensin II (Ang II)-induced cardiac hypertrophy. Circ_0018553 was enriched in endothelial progenitor cell (EPC)-derived exosomes, and circ_0018553 expression was downregulated in a cellular model of Ang II-induced cardiac hypertrophy. Silencing circ_0018553 promoted cardiac hypertrophy in the Ang II-induced cardiac hypertrophy cellular model, while overexpression of circ_0018553 significantly attenuated Ang II-induced cardiac hypertrophy in cardiomyocytes. Moreover, mechanistic studies revealed that circ_0018553 acted as a sponge for miR-4731 and that miR-4731 repressed sirtuin 2 (SIRT2) expression by targeting the 3'UTR of SIRT2. MiR-4731 overexpression promoted cardiac hypertrophy in the Ang II-induced cardiac hypertrophy cellular model, while inhibition of miR-4731 significantly attenuated Ang II-induced cardiac hypertrophy in cardiomyocytes. The rescue experiments showed that miR-4731 overexpression attenuated the protective effects of circ_0018553 overexpression on the cardiac hypertrophy induced by Ang II; SIRT2 silencing also attenuated the protective effects of miR-4731 inhibition on the Ang II-induced cardiac hypertrophy. In conclusion, our results indicated that EPC-derived exosomal circ_0018553 protected against Ang II-induced cardiac hypertrophy by modulating the miR-4731/SIRT2 signaling pathway.

Indexed as

MicroRNAsMyocytes, CardiacRNA, CircularSirtuin 2Angiotensin IICardiomegalyHumansSignal TransductionAngiotensin IIMicroRNAsRNA, CircularSIRT2 protein, humanSirtuin 2Cardiac hypertrophycirc_0018553EPCsExosomesmiR-4731SIRT2

Identifiers

PMID36474029
OpenAlexW4311115334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.